St. Jude Medical (NYSE:STJ) does not often do flashy deals, but the company has a solid track record of buying just-under-the-radar companies with strong positions in lucrative niche markets. St. Jude rolled out that formula again on Monday, announcing a cash and stock deal for AGA Medical (Nasdaq:AGAM) - a small-cap med-tech company with a great franchise in niche applications of cardiac structural repair and vascular abnormalities.

IN PICTURES: 9 Simple Investing Ratios You Need To Know

The Deal
To bring AGA Medical into the fold, St. Jude is paying about $1.1 billion in a mix of cash and stock, and assuming over $200 million in AGA Medical debt. All told, St. Jude is facing a $1.3 billion price tag, while AGA Medical shareholders get about $20.80 per share divided equally between cash and stock. In order to neutralize the impact of these shares, St. Jude's board also authorized a share repurchase program of up to $600 million. (For more, see The Wacky World Of Mergers And Acquisitions.)

At $20.80, AGA Medical shareholders are getting a better than 40% premium to Friday's closing price. Moreover, the deal values AGAM at over six times 2010 estimated revenue - not quite back to the levels of 8 - 10 times sales seen in the heyday of med-tech M&A at the turn of the century, but a nice premium all the same.

What St. Jude Is Buying
In AGA Medical, St. Jude is buying the leader in catheter-based minimally invasive treatments for many congenital structural defects of the heart. While AGA Medical has a lion's share of this roughly $250 million market, the real value in AGA Medical is its pipeline. The company is pursuing technologically similar minimally invasive approaches to treating patent foramen ovules (PFO) - a heart defect implicated in strokes and migraines. Other R&D efforts include vascular stent grafts and cardiac plugs for left arterial appendage (LAA). All in all, these are four shots on goal for four $1 billion-plus markets. (For more, see A Checklist For Successful Medical Technology Investment.)

Stronger In Cardiology
With this deal, St. Jude definitely strengthens its cardiology franchise - an area that until recently had pretty much gone to sleep in terms of investor and corporate interest. Now, though, Medtronic (NYSE:MDT) and Edwards Lifesciences (NYSE:EW) have investors' attention with their transcatheter heart valves, and Volcano (Nasdaq:VOLC) is showing there is a real business in both intravascular ultrasound imaging and functional measurement (which, technically, is electrophysiology and/or cardiac imaging and not cardiology).

The Bottom Line
It is improbable that this is the start of a new wave of med-tech M&A, any more than relatively recent deals by Medtronic and Covidien were the start of a new wave. Big companies are always on the prowl for innovative approaches that can capture and hold significant marketshare. What it means for investors, though, is that there is real value in small and mid-cap medical technology companies that fit that description - companies doing something new and innovative, treating real problems and possessing the quality and competence to grab real market share. (For more, see Investing In Medical Equipment Companies.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  2. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  3. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  4. Stock Analysis

    Analyzing Sirius XM's Return on Equity (ROE) (SIRI)

    Learn more about the Sirius XM's overall 2015 performance, return on equity performance and future predictions for the company's ROE in 2016 and beyond.
  5. Stock Analysis

    Will Virtusa Corporation's Stock Keep Chugging in 2016? (VRTU)

    Read a thorough review and analysis of Virtusa Corporation's stock looking to project how well the stock is likely to perform for investors in 2016.
  6. Stock Analysis

    Analyzing Porter's Five Forces on JPMorgan Chase (JPM)

    Examine the major money-center bank holding firm, JPMorgan Chase & Company, from the perspective of Porter's five forces model for industry analysis.
  7. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  8. Stock Analysis

    Analyzing Dish Network's Return on Equity (ROE) (DISH, TWC)

    Analyze Dish Network's return on equity (ROE), understand why it has vacillated so greatly in recent years and learn what factors are influencing it.
  9. Fundamental Analysis

    5 Must-Have Metrics For Value Investors

    Focusing on certain fundamental metrics is the best way for value investors to cash in gains. Here are the most important metrics to know.
  10. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  1. When does a growth stock turn into a value opportunity?

    A growth stock turns into a value opportunity when it trades at a reasonable multiple of the company's earnings per share ... Read Full Answer >>
  2. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  3. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  4. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  5. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  6. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
Trading Center